百济神州“增长之问”:泽布替尼美国市占率登顶后,下一个五年能走多远?

动脉新医药
Mar 04

从发布2025年度业绩快报和2026年业绩预测至今,百济神州在A股、港股和美股均未明显上涨。但是2025年是百济神州12年来首次全年盈利,而且根据国投证券研报数据,2025年Q3,泽布替尼的美国市场占有率达到33.8%,超过伊布替尼成为第一名,全球市场占有率也在2025年Q4突破30%。然而股价表现却存在反差,动脉网从多位医疗领域业内人士处了解到,这可能与市场对泽布替尼的预期有关,大家普遍关注泽布...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10